Can you keep weight off after Wegovy? What the evidence says

What the STEP 1 extension trial tells us about stopping semaglutide

The most direct evidence on keeping weight off after Wegovy comes from the STEP 1 trial's withdrawal extension. In the main STEP 1 study, adults taking semaglutide 2.4 mg alongside lifestyle support achieved an average body-weight reduction of around 15% over 68 weeks. When a subset then stopped the medicine and continued lifestyle support alone, they regained an average of roughly two-thirds of that lost weight within the following 52 weeks. Body-weight and waist circumference both moved back towards baseline. The full STEP 1 findings, published in the New England Journal of Medicine, make clear that semaglutide's effects depend on its continued presence, it is not re-setting a biological set-point permanently.

This is not a flaw in the medicine. Obesity is a chronic condition shaped by hormonal signals, not a problem that resolves after a course of treatment the way a bacterial infection might. The GLP-1 receptors that semaglutide acts on are part of a system the body actively works to defend. Once treatment stops, appetite-regulating hormones return to their pre-treatment patterns, hunger increases, and without deliberate countermeasures weight tends to follow.

Understanding this is the starting point for any realistic plan. The question is not whether the biology pushes back (it does) but what tools are available to push back harder.

What actually protects results: the evidence on lifestyle foundations

The STEP 1 extension showed something else worth noting: participants who kept more of their weight off after stopping were those who maintained the behavioural changes built during treatment. That is consistent with what NHS England's guidance on weight-management injections describes as "wrap-around" care: dietary support, physical activity, and behaviour-change input delivered alongside the medicine, not instead of it.

Three areas have the clearest practical support in the literature. Protein intake matters disproportionately, adequate protein helps preserve lean muscle mass during weight loss, and more muscle means a higher resting metabolic rate to defend against regain. Resistance or strength-based activity compounds this; people who build it during treatment carry a metabolic advantage into the period after stopping. Sleep quality is less discussed but well-evidenced: short or disrupted sleep raises ghrelin (a hunger signal) and impairs satiety responses, precisely the pathways semaglutide was suppressing.

None of these replace the medicine, and none of them is a guarantee. But they represent the margin of difference between people who keep a meaningful proportion of their results and those who return close to baseline. Building them during treatment, rather than after, is when it is easiest, appetite suppression during active treatment makes dietary changes less effortful to sustain.

If you are weighing up your options, our page on keeping weight off after Wegovy covers the practical side of this in more depth, including how to approach the transition period with your clinical team.

The case for continuing treatment, and what the alternatives look like

For many people, the most evidence-backed answer to how to keep the weight off after semaglutide is not to stop, and understanding the full picture of what supports lasting results is worth doing before any decision is made. UK prescribing guidance does not set an automatic end-date for semaglutide in private treatment; the decision is a clinical one based on benefit, tolerability and individual circumstances. Continuing at the lowest effective maintenance dose while consolidating lifestyle changes is a legitimate long-term strategy, and one that a prescriber can properly assess.

For those who do want to stop, a supervised taper is preferable to an abrupt end, sudden discontinuation removes the appetite-suppressing effect quickly, while a slower reduction gives more time to bed in the habits that will carry the load. Whether and when to stop is a conversation for your prescriber, not a decision to make based on cost or convenience alone. Our page on whether you can keep weight off after stopping Wegovy goes further on that clinical decision.

Some people transition to a different licensed medicine. Tirzepatide, available in the UK as Mounjaro, acts on both GLP-1 and GIP receptors and has shown greater average weight reduction in head-to-head trials; whether that makes it the right next step is a question for a prescriber who knows your history. If you want to understand the wider landscape of licensed weight-loss treatment options, that is worth reviewing before any consultation.

What the evidence does not support is stopping treatment without a plan and hoping the lifestyle changes hold on their own. For most people, they do not, not fully. That is worth knowing before the decision is made, not after.

Starting a conversation with a prescriber about your options

The practical shape of any post-Wegovy plan depends on factors a prescriber needs to know: how long you have been on treatment, your current dose, how much weight you have lost, what comorbidities are in the picture, and what your goals are going forward. These are not questions with a universal answer, and online resources (including this one) can frame the evidence but cannot replace that clinical conversation.

At nume, every repeat order is reviewed by a GPhC-registered prescriber before it goes ahead; there are no auto-renewals and no prescriptions issued without a clinical re-assessment. That structure exists precisely because ongoing treatment decisions matter. If you are approaching the end of a course, uncertain whether to continue, or thinking about what comes next, how long you can stay on semaglutide is a useful starting point for understanding the clinical parameters.

For people considering starting treatment (or restarting after a gap), our Wegovy before and afters page gives a grounded sense of what outcomes look like in practice before you book a consultation. There is no obligation, no algorithm reading your answers, and no same-day rush: a real clinician reviews what you submit and responds the same day. Your treatment, if approved, arrives via DPD the next working day in plain, unbranded packaging, straightforward from the first step.